Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2025)

Tarsus Pharmaceuticals has reported Gross Profit over the past 5 years, most recently at $140.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $140.7 million for Q4 2025, up 128.91% from a year ago — trailing twelve months through Dec 2025 was $420.7 million (up 147.27% YoY), and the annual figure for FY2025 was $420.7 million, up 147.27%.
  • Gross Profit for Q4 2025 was $140.7 million at Tarsus Pharmaceuticals, up from $110.4 million in the prior quarter.
  • Over the last five years, Gross Profit for TARS hit a ceiling of $140.7 million in Q4 2025 and a floor of $362000.0 in Q4 2021.
  • Median Gross Profit over the past 5 years was $23.6 million (2021), compared with a mean of $38.1 million.
  • Biggest five-year swings in Gross Profit: crashed 98.43% in 2022 and later soared 2903.75% in 2024.
  • Tarsus Pharmaceuticals' Gross Profit stood at $362000.0 in 2021, then soared by 2551.93% to $9.6 million in 2022, then increased by 23.54% to $11.9 million in 2023, then skyrocketed by 418.4% to $61.5 million in 2024, then surged by 128.91% to $140.7 million in 2025.
  • The last three reported values for Gross Profit were $140.7 million (Q4 2025), $110.4 million (Q3 2025), and $96.4 million (Q2 2025) per Business Quant data.